SUPPLEMENT

Q2 2025 — Financial disclosures

Q2 2025PDF · 10 pages541 KB
Merck & Co., Inc.,
Rahway, N.J., USA
Financial Highlights Package
Second Quarter 2025
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 2Q25 and June YTD 25.......3
Table 2b: GAAP to Non-GAAP Reconciliation 2Q24 and June YTD 24.......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / International 2Q25.................................................6
Table 3b: Sales – U.S. / International June YTD 25.....................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	15,529	$ 	15,806	$ 	31,335	$ 	15,775	$ 	16,112	$ 	31,887	$ 	16,657	$ 	15,624	$ 	64,168	$ 	-2% 	-2%
Costs, Expenses and Other
Cost of sales 	3,419 	3,557 	6,976 	3,540 	3,745 	7,285 	4,080 	3,828 	15,193 	-5% 	-4%
Selling, general and administrative 	2,552 	2,649 	5,202 	2,483 	2,739 	5,221 	2,731 	2,864 	10,816 	-3% 	0%
Research and development 	3,621 	4,048 	7,669 	3,992 	3,500 	7,492 	5,862 	4,585 	17,938 	16% 	2%
Restructuring costs 	69 	560 	629 	123 	80 	202 	56 	51 	309 	* 	*
Other (income) expense, net 	(35) 	(7) 	(43) 	(33) 	42 	12 	(162) 	126 	(24) 	* 	*
Income Before Taxes 	5,903 	4,999 	10,902 	5,670 	6,006 	11,675 	4,090 	4,170 	19,936 	-17% 	-7%
Income Tax Provision 	818 	571 	1,388 	903 	545 	1,447 	929 	425 	2,803
Net Income 	5,085 	4,428 	9,514 	4,767 	5,461 	10,228 	3,161 	3,745 	17,133 	-19% 	-7%
Less: Net Income Attributable to Noncontrolling Interests 	6 	1 	8 	5 	6 	11 	4 	2 	16
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	5,079	$ 	4,427	$ 	9,506	$ 	4,762	$ 	5,455	$ 	10,217	$ 	3,157	$ 	3,743	$ 	17,117	$ 	-19% 	-7%
Earnings per Common Share Assuming Dilution 	2.01	$ 	1.76	$ 	3.77	$ 	1.87	$ 	2.14	$ 	4.02	$ 	1.24	$ 	1.48	$ 	6.74	$ 	-18% 	-6%
Average Shares Outstanding Assuming Dilution 	2,531 	2,513 	2,522 	2,544 	2,544 	2,544 	2,541 	2,537 	2,541
Tax Rate 	13.9% 	11.4% 	12.7% 	15.9% 	9.1% 	12.4% 	22.7% 	10.2% 	14.1%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
2Q 	June YTD
% Change
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
Full Year
2025
2Q	1Q 	1Q 	2Q 	3Q
2024
June YTD 	June YTD 	4Q

-- 2 of 10 --

Sales 	15,806	$ 	16,112	$ 	-2% 	31,335	$ 	31,887	$ 	-2%
Costs, Expenses and Other
Cost of sales 	3,557 	3,745 	-5% 	6,976 	7,285 	-4%
Selling, general and administrative 	2,649 	2,739 	-3% 	5,202 	5,221 	0%
Research and development 	4,048 	3,500 	16% 	7,669 	7,492 	2%
Restructuring costs 	560 	80 	* 	629 	202 	*
Other (income) expense, net 	(7) 	42 	* 	(43) 	12 	*
Income Before Taxes 	4,999 	6,006 	-17% 	10,902 	11,675 	-7%
Income Tax Provision 	571 	545 	1,388 	1,447
Net Income 	4,428 	5,461 	-19% 	9,514 	10,228 	-7%
Less: Net Income Attributable to Noncontrolling Interests 	1 	6 	8 	11
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	4,427	$ 	5,455	$ 	-19% 	9,506	$ 	10,217	$ 	-7%
Earnings per Common Share Assuming Dilution 	1.76	$ 	2.14	$ 	-18% 	3.77	$ 	4.02	$ 	-6%
Average Shares Outstanding Assuming Dilution 	2,513 	2,544 	2,522 	2,544
Tax Rate 	11.4% 	9.1% 	12.7% 	12.4%
* 100% or greater
GAAP
% Change	June YTD
2025
June YTD
2024
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
2Q25 	2Q24

-- 3 of 10 --

Second Quarter
Cost of sales 	3,557	$ 	576 	165 	741 	2,816	$
Selling, general and administrative 	2,649 	15 	1 	16 	2,633
Research and development 	4,048 	3 	53 	56 	3,992
Restructuring costs 	560 	560 	560 	–
Other (income) expense, net 	(7) 	(61) 	(61) 	54
Income Before Taxes 	4,999 	(594) 	(779) 	61 	(1,312) 	6,311
Income Tax Provision (Benefit) 	571 	(102) (3) 	(139) (3) 	14 (3) 	(146) (4) 	(373) 	944
Net Income 	4,428 	(492) 	(640) 	47 	146 	(939) 	5,367
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	4,427 	(492) 	(640) 	47 	146 	(939) 	5,366
Earnings per Common Share Assuming Dilution 	1.76	$ 	(0.20) 	(0.25) 	0.02 	0.06 	(0.37) 	2.13	$
Tax Rate 	11.4% 	15.0%
June YTD
Cost of sales 	6,976	$ 	1,196 	201 	1,397 	5,579	$
Selling, general and administrative 	5,202 	38 	1 	39 	5,163
Research and development 	7,669 	10 	53 	63 	7,606
Restructuring costs 	629 	629 	629 	–
Other (income) expense, net 	(43) 	(3) 	(168) 	(171) 	128
Income Before Taxes 	10,902 	(1,241) 	(884) 	168 	(1,957) 	12,859
Income Tax Provision (Benefit) 	1,388 	(219) (3) 	(157) (3) 	36 (3) 	(146) (4) 	(486) 	1,874
Net Income 	9,514 	(1,022) 	(727) 	132 	146 	(1,471) 	10,985
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	9,506 	(1,022) 	(727) 	132 	146 	(1,471) 	10,977
Earnings per Common Share Assuming Dilution 	3.77	$ 	(0.40) 	(0.29) 	0.05 	0.06 	(0.58) 	4.35	$
Tax Rate 	12.7% 	14.6%
Only the line items that are affected by non-GAAP adjustments are shown.
(4) Represents tax benefits primarily resulting from favorable audit adjustments.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and
forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income
metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets and intangible asset impairment charges, partially offset by a decrease in the estimated fair value measurement of liabilities for contingent
consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect
the amortization of intangible assets.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND SIX MONTHS ENDED JUNE 30, 2025 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
GAAP 	Acquisition- and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal 	Non-GAAP	Certain Other Items

-- 4 of 10 --

Second Quarter
Cost of sales 	3,745	$ 	606 	66 	672 	3,073	$
Selling, general and administrative 	2,739 	24 	31 	55 	2,684
Research and development 	3,500 	20 	20 	3,480
Restructuring costs 	80 	80 	80 	–
Other (income) expense, net 	42 	(17) 	(49) 	(66) 	108
Income Before Taxes 	6,006 	(633) 	(177) 	49 	(761) 	6,767
Income Tax Provision (Benefit) 	545 	(129) (3) 	(30) (3) 	11 (3) 	(259) (4) 	(407) 	952
Net Income 	5,461 	(504) 	(147) 	38 	259 	(354) 	5,815
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	5,455 	(504) 	(147) 	38 	259 	(354) 	5,809
Earnings per Common Share Assuming Dilution 	2.14	$ 	(0.20) 	(0.06) 	0.02 	0.10 	(0.14) 	2.28	$
Tax Rate 	9.1% 	14.1%
June YTD
Cost of sales 	7,285	$ 	1,069 	182 	1,251 	6,034	$
Selling, general and administrative 	5,221 	45 	36 	81 	5,140
Research and development 	7,492 	36 	2 	38 	7,454
Restructuring costs 	202 	202 	202 	–
Other (income) expense, net 	12 	(21) 	(165) 	(186) 	198
Income Before Taxes 	11,675 	(1,129) 	(422) 	165 	(1,386) 	13,061
Income Tax Provision (Benefit) 	1,447 	(221) (3) 	(72) (3) 	36 (3) 	(259) (4) 	(516) 	1,963
Net Income 	10,228 	(908) 	(350) 	129 	259 	(870) 	11,098
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	10,217 	(908) 	(350) 	129 	259 	(870) 	11,087
Earnings per Common Share Assuming Dilution 	4.02	$ 	(0.35) 	(0.14) 	0.05 	0.10 	(0.34) 	4.36	$
Tax Rate 	12.4% 	15.0%
Only the line items that are affected by non-GAAP adjustments are shown.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-
GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information
presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and
divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-
Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND SIX MONTHS ENDED JUNE 30, 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
Non-GAAP	Certain Other Items 	Adjustment Subtotal

-- 5 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2025 	2024 	2Q 	June YTD
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	Nom % Ex-Exch % 	Nom % Ex-Exch %
TOTAL SALES (1) 	$15,529 	$15,806 	$31,335 	$15,775 	$16,112 	$31,887 	$16,657 	$15,624 	$64,168 	-2 	-2 	-2 	0
PHARMACEUTICAL 	13,638 	14,050 	27,688 	14,006 	14,408 	28,415 	14,943 	14,042 	57,400 	-2 	-3 	-3 	-2
Oncology
Keytruda 	7,205 	7,956 	15,161 	6,947 	7,270 	14,217 	7,429 	7,836 	29,482 	9 	9 	7 	8
Alliance Revenue – Lynparza (2) 	312 	370 	682 	292 	317 	609 	337 	365 	1,311 	17 	15 	12 	12
Alliance Revenue – Lenvima (2) 	258 	265 	523 	255 	249 	504 	251 	255 	1,010 	6 	5 	4 	4
Welireg 	137 	162 	300 	85 	126 	211 	139 	160 	509 	29 	29 	42 	43
Alliance Revenue – Reblozyl (3) 	119 	107 	226 	71 	90 	161 	100 	110 	371 	19 	19 	40 	40
Vaccines (4)
Gardasil/Gardasil 9 	1,327 	1,126 	2,453 	2,249 	2,478 	4,727 	2,306 	1,550 	8,583 	-55 	-55 	-48 	-48
ProQuad/M-M-R II/Varivax 	539 	609 	1,148 	570 	617 	1,187 	703 	594 	2,485 	-1 	-2 	-3 	-3
Vaxneuvance 	230 	229 	459 	219 	189 	408 	239 	161 	808 	21 	20 	13 	13
RotaTeq 	228 	121 	349 	216 	163 	379 	193 	139 	711 	-26 	-26 	-8 	-7
Capvaxive 	107 	129 	236 	47 	50 	97 	- 	- 	- 	-
Pneumovax 23 	41 	38 	79 	61 	59 	120 	68 	74 	263 	-36 	-37 	-35 	-33
Hospital Acute Care
Bridion 	441 	461 	902 	440 	455 	895 	420 	449 	1,764 	1 	1 	1 	1
Prevymis 	208 	228 	436 	174 	188 	362 	208 	215 	785 	21 	20 	20 	21
Dificid 	83 	96 	179 	73 	92 	165 	96 	79 	340 	5 	5 	8 	9
Zerbaxa 	70 	74 	145 	56 	62 	118 	64 	70 	252 	21 	21 	23 	24
Cardiovascular
Winrevair 	280 	336 	615 	70 	70 	149 	200 	419 	* 	* 	* 	*
Alliance Revenue - Adempas/Verquvo (5) 	106 	123 	229 	98 	106 	203 	102 	109 	415 	16 	16 	12 	12
Adempas (6) 	68 	80 	147 	70 	72 	142 	72 	73 	287 	10 	6 	4 	4
Virology
Lagevrio 	102 	83 	185 	350 	110 	460 	383 	121 	964 	-25 	-27 	-60 	-59
Isentress/Isentress HD 	90 	86 	176 	111 	89 	200 	102 	92 	394 	-3 	-4 	-12 	-11
Delstrigo 	67 	83 	150 	56 	60 	116 	65 	69 	249 	40 	35 	30 	30
Pifeltro 	45 	41 	86 	42 	39 	81 	42 	40 	163 	5 	4 	6 	6
Neuroscience
Belsomra 	50 	40 	90 	46 	53 	99 	78 	45 	222 	-24 	-26 	-9 	-8
Immunology
Simponi 	184 	172 	356 	189 	543 	-100 	-100 	-100 	-100
Remicade 	39 	35 	74 	41 	114 	-100 	-100 	-100 	-100
Diabetes (7)
Januvia 	549 	372 	921 	419 	405 	824 	278 	232 	1,334 	-8 	-8 	12 	13
Janumet 	247 	251 	498 	251 	224 	475 	204 	255 	935 	12 	14 	5 	8
Other Pharmaceutical (8) 	729 	584 	1,313 	632 	618 	1,252 	638 	699 	2,590 	-6 	-7 	5 	6
ANIMAL HEALTH 	1,588 	1,646 	3,234 	1,511 	1,482 	2,993 	1,487 	1,397 	5,877 	11 	11 	8 	11
Livestock 	924 	961 	1,885 	850 	837 	1,686 	886 	889 	3,462 	15 	16 	12 	16
Companion Animal 	664 	685 	1,349 	661 	645 	1,307 	601 	508 	2,415 	6 	6 	3 	4
Other Revenues (9) 	303 	110 	413 	258 	222 	479 	227 	185 	891 	-50 	-3 	-14 	7
*200% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $876 million and $704 million in the first and second quarter of 2025, respectively, and $745 million and $715 million in the first and second quarter of 2024.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $95 million and $5 million in the first and second quarter of 2025, respectively, and $61 million and $15 million
in the first and second quarter of 2024, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,607 million and $2,370 million in the first and second quarter of 2025, respectively, and $3,424 million and $3,656 million in the first and second quarter of 2024,
respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in the Company's marketing territories.

-- 6 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2025
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
2Q 2025 	2Q 2024 % Change 	2Q 2025 	2Q 2024 % Change 	2Q 2025 	2Q 2024 % Change
TOTAL SALES (1) 	$15,806 	$16,112 	-2 	$8,836 	$7,876 	12 	$6,969 	$8,236 	-15
PHARMACEUTICAL 	14,050 	14,408 	-2 	8,328 	7,399 	13 	5,722 	7,009 	-18
Oncology
Keytruda 	7,956 	7,270 	9 	4,749 	4,412 	8 	3,207 	2,858 	12
Alliance Revenue – Lynparza (2) 	370 	317 	17 	174 	153 	14 	195 	165 	19
Alliance Revenue – Lenvima (2) 	265 	249 	6 	183 	177 	3 	83 	73 	14
Welireg 	162 	126 	29 	138 	116 	19 	24 	10 	155
Alliance Revenue – Reblozyl (3) 	107 	90 	19 	88 	75 	18 	19 	15 	24
Vaccines (4)
Gardasil/Gardasil 9 	1,126 	2,478 	-55 	545 	536 	2 	581 	1,941 	-70
ProQuad/M-M-R II/Varivax 	609 	617 	-1 	481 	490 	-2 	128 	127 	1
Vaxneuvance 	229 	189 	21 	136 	99 	38 	93 	90 	3
Capvaxive 	129 	- 	129 	-
RotaTeq 	121 	163 	-26 	60 	107 	-44 	61 	56 	9
Pneumovax 23 	38 	59 	-36 	5 	11 	-57 	33 	48 	-31
Hospital Acute Care
Bridion 	461 	455 	1 	411 	351 	17 	50 	104 	-52
Prevymis 	228 	188 	21 	115 	90 	27 	113 	98 	16
Dificid 	96 	92 	5 	83 	79 	4 	13 	12 	8
Zerbaxa 	74 	62 	21 	45 	33 	35 	29 	28 	5
Cardiovascular
Winrevair 	336 	70 	* 	323 	70 	* 	12 	-
Alliance Revenue - Adempas/Verquvo (5) 	123 	106 	16 	108 	98 	10 	15 	8 	89
Adempas (6) 	80 	72 	10 	80 	72 	10
Virology
Isentress/Isentress HD 	86 	89 	-3 	48 	43 	13 	38 	46 	-18
Delstrigo 	83 	60 	40 	14 	14 	-5 	70 	45 	55
Lagevrio 	83 	110 	-25 	30 	15 	103 	52 	95 	-45
Pifeltro 	41 	39 	5 	25 	27 	-4 	16 	12 	26
Neuroscience
Belsomra 	40 	53 	-24 	18 	19 	-1 	21 	34 	-37
Immunology
Simponi 	172 	-100 	172 	-100
Remicade 	35 	-100 	35 	-100
Diabetes (7)
Januvia 	372 	405 	-8 	216 	177 	22 	155 	227 	-32
Janumet 	251 	224 	12 	68 	17 	* 	184 	208 	-12
Other Pharmaceutical (8) 	584 	618 	-6 	136 	190 	-28 	450 	430 	5
ANIMAL HEALTH 	1,646 	1,482 	11 	499 	455 	9 	1,147 	1,027 	12
Livestock 	961 	837 	15 	190 	168 	13 	771 	669 	15
Companion Animal 	685 	645 	6 	309 	287 	8 	376 	358 	5
Other Revenues (9) 	110 	222 	-50 	9 	22 	-59 	100 	200 	-50
*200% or greater
(6) Net product sales in the Company's marketing territories.
(7) Total Diabetes sales were $704 million and $715 million on a global basis in the second quarter of 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $5 million and $15
million in the second quarter of 2025 and 2024, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,370 million and $3,656 million on a global basis in the second quarter of 2025 and 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.

-- 7 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
JUNE YEAR-TO-DATE 2025
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
June YTD
2025
June YTD
2024 	% Change
June YTD
2025
June YTD
2024 	% Change
June YTD
2025
June YTD
2024 	% Change
TOTAL SALES (1) 	$31,335 	$31,887 	-2 	$17,359 	$15,354 	13 	$13,977 	$16,533 	-15
PHARMACEUTICAL 	27,688 	28,415 	-3 	16,254 	14,336 	13 	11,434 	14,079 	-19
Oncology
Keytruda 	15,161 	14,217 	7 	9,057 	8,531 	6 	6,104 	5,686 	7
Alliance Revenue – Lynparza (2) 	682 	609 	12 	319 	288 	11 	363 	321 	13
Alliance Revenue – Lenvima (2) 	523 	504 	4 	368 	349 	5 	155 	155 	-
Welireg 	300 	211 	42 	261 	194 	35 	39 	17 	130
Alliance Revenue – Reblozyl (3) 	226 	161 	40 	189 	133 	42 	37 	28 	34
Vaccines (4)
Gardasil/Gardasil 9 	2,453 	4,727 	-48 	1,082 	1,024 	6 	1,371 	3,702 	-63
ProQuad/M-M-R II/Varivax 	1,148 	1,187 	-3 	903 	928 	-3 	245 	259 	-6
Vaxneuvance 	459 	408 	13 	275 	260 	6 	184 	148 	25
RotaTeq 	349 	379 	-8 	225 	257 	-12 	125 	123 	2
Capvaxive 	236 	- 	235 	- 	1 	-
Pneumovax 23 	79 	120 	-35 	3 	17 	-82 	76 	103 	-27
Hospital Acute Care
Bridion 	902 	895 	1 	789 	680 	16 	113 	215 	-47
Prevymis 	436 	362 	20 	217 	165 	32 	219 	197 	11
Dificid 	179 	165 	8 	155 	147 	5 	24 	17 	39
Zerbaxa 	145 	118 	23 	87 	67 	31 	57 	51 	12
Cardiovascular
Winrevair 	615 	70 	* 	591 	70 	* 	24 	-
Alliance Revenue - Adempas/Verquvo (5) 	229 	203 	12 	205 	188 	9 	23 	16 	50
Adempas (6) 	147 	142 	4 	147 	142 	4
Virology
Lagevrio 	185 	460 	-60 	66 	60 	10 	119 	400 	-70
Isentress/Isentress HD 	176 	200 	-12 	99 	93 	7 	77 	107 	-28
Delstrigo 	150 	116 	30 	29 	26 	10 	121 	89 	36
Pifeltro 	86 	81 	6 	57 	56 	2 	29 	25 	14
Neuroscience
Belsomra 	90 	99 	-9 	31 	33 	-5 	58 	66 	-12
Immunology
Simponi 	356 	-100 	356 	-100
Remicade 	74 	-100 	74 	-100
Diabetes (7)
Januvia 	921 	824 	12 	561 	361 	55 	360 	463 	-22
Janumet 	498 	475 	5 	133 	55 	140 	366 	420 	-13
Other Pharmaceutical (8) 	1,313 	1,252 	5 	317 	354 	-10 	997 	899 	11
ANIMAL HEALTH 	3,234 	2,993 	8 	1,001 	929 	8 	2,233 	2,064 	8
Livestock 	1,885 	1,686 	12 	384 	334 	15 	1,501 	1,352 	11
Companion Animal 	1,349 	1,307 	3 	617 	595 	4 	732 	712 	3
Other Revenues (9) 	413 	479 	-14 	104 	89 	17 	310 	390 	-21
*200% or greater
(6) Net product sales in the Company's marketing territories.
(7) Total Diabetes sales were $1,580 million and $1,461 million on a global basis for June YTD 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $100 million and $76
million on a global basis for June YTD 2025 and 2024, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $4,977 million and $7,080 million on a global basis for June YTD 2025 and 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.

-- 8 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2025 	2024 	% Change
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	2Q 	June YTD
TOTAL PHARMACEUTICAL 	$13,638 	$14,050 	$27,688 	$14,006 	$14,408 	$28,415 	$14,943 	$14,042 	$57,400 	-2 	-3
United States 	7,927 	8,328 	16,254 	6,936 	7,399 	14,336 	8,227 	7,728 	30,290 	13 	13
% Pharmaceutical Sales 	58.1% 	59.3% 	58.7% 	49.5% 	51.4% 	50.5% 	55.1% 	55.0% 	52.8%
Europe (1) 	2,384 	2,551 	4,935 	2,555 	2,572 	5,128 	2,620 	2,498 	10,246 	-1 	-4
% Pharmaceutical Sales 	17.5% 	18.2% 	17.8% 	18.2% 	17.9% 	18.0% 	17.5% 	17.8% 	17.9%
Japan 	651 	604 	1,255 	802 	664 	1,466 	919 	813 	3,199 	-9 	-14
% Pharmaceutical Sales 	4.8% 	4.3% 	4.5% 	5.7% 	4.6% 	5.2% 	6.2% 	5.8% 	5.6%
Latin America 	589 	654 	1,243 	601 	661 	1,262 	730 	680 	2,672 	-1 	-2
% Pharmaceutical Sales 	4.3% 	4.7% 	4.5% 	4.3% 	4.6% 	4.4% 	4.9% 	4.8% 	4.7%
Asia Pacific (other than China and Japan) 	535 	609 	1,144 	580 	595 	1,175 	669 	612 	2,457 	2 	-3
% Pharmaceutical Sales 	3.9% 	4.3% 	4.1% 	4.1% 	4.1% 	4.1% 	4.5% 	4.4% 	4.3%
China (2) 	668 	407 	1,075 	1,744 	1,790 	3,534 	996 	864 	5,394 	-77 	-70
% Pharmaceutical Sales 	4.9% 	2.9% 	3.9% 	12.5% 	12.4% 	12.4% 	6.7% 	6.2% 	9.4%
Eastern Europe/Middle East/Africa 	435 	451 	886 	395 	353 	747 	400 	348 	1,495 	28 	19
% Pharmaceutical Sales 	3.2% 	3.2% 	3.2% 	2.8% 	2.4% 	2.6% 	2.7% 	2.5% 	2.6%
Canada 	125 	135 	261 	138 	143 	281 	133 	144 	558 	-6 	-7
% Pharmaceutical Sales 	0.9% 	1.0% 	0.9% 	1.0% 	1.0% 	1.0% 	0.9% 	1.0% 	1.0%
Other 	324 	311 	635 	255 	231 	486 	249 	355 	1,089 	35 	31
% Pharmaceutical Sales 	2.4% 	2.1% 	2.4% 	1.9% 	1.6% 	1.8% 	1.5% 	2.5% 	1.7%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
(2) Gardasil/Gardasil 9 sales in China were $193 million and $0 in the first and second quarter of 2025, respectively, and $1,253 million, $1,312 million, $517 million and $446 million in the first,
second, third and fourth quarter of 2024, respectively.

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
2Q25 	2Q24
June YTD
2025
June YTD
2024
Interest income 	(69)	$ 	(69)	$ 	(178)	$ 	(141)	$
Interest expense 	305 	310 	618 	613
Exchange losses 	78 	60 	167 	144
Income from investments in equity securities, net (1) 	(100) 	(56) 	(189) 	(200)
Net periodic defined benefit plan (credit) cost other than service cost 	(152) 	(159) 	(300) 	(319)
Other, net 	(69) 	(44) 	(161) 	(85)
Total 	(7)	$ 	42	$ 	(43)	$ 	12	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through
ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at
the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one
quarter lag.
MERCK & CO., INC., RAHWAY, N.J., USA
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4

-- 10 of 10 --